Medium Risk

JB Chemicals & Pharmaceuticals Limited

Chemical & Chemical Products, pharmaceuticals, medicinal chemical & botanical products

CIN: L24390MH1976PLC019380 FY: - Revenue: ₹3,722.9 Cr
5.3
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.1
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
3.0

Financial Exposure

Est. Compliance Cost₹6–22 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated3,518.2 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssuranceAll
Assurance ProviderDNV Business Assurance India Private Limited

Double Materiality

Financial Materiality5.3
Impact Materiality4.6
QuadrantFinancially Material

Supply Chain

MSME Sourcing0.2%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

**JB Chemicals & Pharmaceuticals: Financial Risk Summary** JB Chemicals faces its highest financial exposure through compliance risk (10.0/10 score), with estimated remediation costs of ₹6–22 crore, primarily driven by undefined EPR (Extended Producer Responsibility) applicability and incomplete emissions reporting under SEBI BRSR Core Expansion mandates. The company's critical regulatory gap centers on BRSR P6 environmental disclosure obligations; non-compliance risks include potential SEBI enforcement action and delisting for a ₹3,723 crore revenue-scale company, creating material reputational and market-access damage. While the absence of reported Scope 1 and Scope 2 emissions data raises transparency red flags rather than immediate carbon pricing exposure, the 6.5/10 EPR exposure score indicates unquantified future waste management liabilities under India's plastic and pharmaceutical waste rules—potentially requiring significant capex and operational restructuring. Immediate action on emissions quantification, EPR status clarification, and BRSR disclosure completeness is critical to de-risk compliance penalties and regulatory escalation.

Source: JB Chemicals & Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →